FAM Therapy
PreclinicalSmall molecule
FAM Therapy is one of 14 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Bronchiolitis Obliterans
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Biaxin
AbbVieApproved
Neoral
NovartisApproved
Singulair
OOrganon and Co
Approved
Pulmicort
SSalix
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Foradil
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Esbriet
LLegacy Health System
Approved
Jakafi
IncytePhase 2
Rayos
RRoxane Laboratories
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bronchiolitis Obliterans1 trial
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation
Completed·—··NCT03072849·23 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FAM Therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details